SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing significant selling pressure as 29 states head to trial in a landmark case regarding the impact of social media on younger users. Investors are debating whether this legal overhang and the company's aggressive AI-related capital expenditure represent a long-term risk or a compelling entry point for what many describe as the cheapest mega-cap stock.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is currently trending as investors focus on a recent bullish initiation from Compass Point, which assigned a price target of $44 alongside optimistic long-term revenue and EBITDA projections. The community remains divided, with supporters highlighting massive potential in the company's AI infrastructure and GPU-related commercial book, while short sellers continue to express skepticism regarding SEC filings, potential dilution, and the absence of a confirmed earnings date.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is facing significant market volatility as investors react to a downward revision in full-year guidance and executive leadership transitions. While some community members view the sharp sell-off as an overreaction to temporary headwinds and are actively buying the dip, others are concerned about increased competition and potential market share losses in the fintech space.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is currently facing extreme volatility as investors express deep skepticism over its long-term financial health and business model, with the community actively debating whether the company is a legitimate turnaround story or an unsustainable scheme built on manipulative accounting practices. High levels of institutional short interest and recent reports of federal scrutiny regarding related-party transactions have fueled intense friction between those betting on a potential short squeeze and those convinced the stock is headed toward a structural collapse.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. Its program, avexitide, is a once-daily GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia. Amylyx’s pipeline also includes investigational programs targeting Wolfram syndrome and amyotrophic lateral sclerosis (ALS). The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals is surging following strong Phase 3 LUCIDITY trial results for its avexitide treatment, which met all endpoints and demonstrated a significant reduction in severe hypoglycemic events. Investors are buzzing about the company's clear path to an NDA filing, a robust cash position through 2028, and widespread speculation regarding potential acquisition interest from major pharmaceutical players.

Angel Studios, Inc. is a values-based distribution company for stories that amplify light to mainstream audiences. The company is headquartered in Provo, UT.

Angel Studios Inc. - Ordinary Shares - Class A

Angel Studios Inc

Angel Studios is attracting significant investor attention following the launch of a real-time Guild membership tracker, a key metric that highlights the company's recurring revenue growth and box office synergy. The community is buzzing over strong subscriber momentum and anticipating a potential breakout ahead of the upcoming Young Washington theatrical release.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlist is trending as retail investors rally behind the stock, anticipating a massive short squeeze and further gains driven by ongoing legal victories against memory giants. The community is focused on recent settlement news and the potential for upcoming deals with major industry players to accelerate long-term valuation growth.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is facing intense downward pressure following a disappointing earnings report that highlighted cooling growth in its AI cloud infrastructure and continued weakness in its core online marketing business. The community is sharply divided, with some investors viewing the pullback as a buying opportunity given the company's AI-focused transition, while others remain skeptical about the long-term profitability of these initiatives and the impact of the slowing revenue growth.

Fabrinet engages in the provision of optical packaging and electronic manufacturing services to original equipment manufacturers. The firm's engineering services include process design, failure analysis, reliability testing, tooling design, and real-time traceability system. Its manufacturing operations offer sensors, subsystems, customized optics, and optical modules and components. The company was founded by David Thomas Mitchell on August 12, 1999 and is headquartered in George Town, Cayman Islands.

Fabrinet

Fabrinet shares are experiencing significant volatility as investors digest a fiscal Q4 earnings report that beat expectations but disappointed on margins and cash flow. While analysts have raised price targets following the solid top-line performance, the community remains divided between those viewing the sell-off as a buying opportunity and others concerned about institutional distribution and valuation.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending as retail investors debate its potential for a turnaround, with many highlighting its low valuation and active insider buying as reasons for a possible recovery. While sentiment remains polarized due to leadership transitions and shifting consumer preferences, community discussion is heavily focused on whether the stock's current price point represents a generational entry opportunity or a lingering value trap.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues

AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.

Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio

Jazz Pharmaceuticals will acquire Actio Biosciences, Inc., a deal that expands Jazz's pipeline and presence in rare epilepsy treatments...

Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects

Explore Jazz's (JAZZ) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio PR Newswire DUBLIN and SAN DIEGO, Aug. 10, 2026 Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for...

Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

JAZZ vs. TECH: Which Stock Is the Better Value Option?

JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View

Jazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss, as strong oncology and neuroscience demand lifts shares.

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results

Jazz Pharmaceuticals (JAZZ) reported Q2 sales above estimates and raised its FY26 sales guidance. Analysts have mixed opinions, with some raising price targets. Consider buying JAZZ stock.read more...

Compared to Estimates, Jazz (JAZZ) Q2 Earnings: A Look at Key Metrics

The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Jazz Pharmaceuticals (JAZZ) Q2 Earnings Lag Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of -5.46% and +9.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

$JAZZ Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of $3.05 up 125.98% YoY
• Reported revenue of $1.21B up 15.55% YoY

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc

Retail Traders Cheer Jazz Pharma After FDA Clears Rare Drug For Brain Tumor

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$254.13
Prev Close	$248.36
Open	$248.74
Dividend Yield	0.00%
50-Day Moving Average	$243.18
Beta	0.71
Avg. Volume	709,361.07
PE Ratio	17.13

52-Week High	$265.05
52-Week Low	$117.70
Market Capitalization	$16.12B
EPS (Annual)	-$5.84
Price to Book	3.35
Revenue Per Employee	$1.48M

Feed

News

Sentiment

Earnings

Fundamentals

Info